Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference
Regulus Therapeutics (Nasdaq: RGLS), a biopharmaceutical company specializing in microRNA-targeted medicine development, has announced its upcoming participation at the Leerink Partners 2025 Global Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, March 11th at 3:40 p.m. ET.
Investors and interested parties can access both the live presentation and its replay through the 'Events and Presentations' section on Regulus' investor relations website. The presentation recording will remain accessible for 90 days following the event.
Regulus Therapeutics (Nasdaq: RGLS), un'azienda biofarmaceutica specializzata nello sviluppo di medicine mirate ai microRNA, ha annunciato la sua prossima partecipazione alla Conferenza Globale sulla Sanità 2025 di Leerink Partners. Il team di gestione dell'azienda parteciperà a una conversazione informale programmata per martedì 11 marzo alle 15:40 ET.
Gli investitori e le parti interessate possono accedere sia alla presentazione dal vivo che alla sua registrazione attraverso la sezione 'Eventi e Presentazioni' sul sito web delle relazioni con gli investitori di Regulus. La registrazione della presentazione rimarrà accessibile per 90 giorni dopo l'evento.
Regulus Therapeutics (Nasdaq: RGLS), una compañía biofarmacéutica especializada en el desarrollo de medicamentos dirigidos a microARN, ha anunciado su próxima participación en la Conferencia Global de Salud 2025 de Leerink Partners. El equipo directivo de la compañía participará en una charla informal programada para el martes 11 de marzo a las 3:40 p.m. ET.
Los inversores y partes interesadas pueden acceder tanto a la presentación en vivo como a su repetición a través de la sección 'Eventos y Presentaciones' en el sitio web de relaciones con inversores de Regulus. La grabación de la presentación permanecerá accesible durante 90 días después del evento.
Regulus Therapeutics (Nasdaq: RGLS), 마이크로RNA를 표적으로 하는 의약품 개발에 특화된 생명공학 회사가 Leerink Partners 2025 글로벌 헬스케어 컨퍼런스에 참여할 예정이라고 발표했습니다. 회사의 경영팀은 3월 11일 화요일 오후 3시 40분 ET에 예정된 대화에 참여할 것입니다.
투자자와 이해관계자는 Regulus의 투자자 관계 웹사이트의 '이벤트 및 프레젠테이션' 섹션을 통해 라이브 프레젠테이션과 그 재생을 모두 접근할 수 있습니다. 프레젠테이션 녹화는 이벤트 이후 90일 동안 접근 가능할 것입니다.
Regulus Therapeutics (Nasdaq: RGLS), une entreprise biopharmaceutique spécialisée dans le développement de médicaments ciblant les microARN, a annoncé sa prochaine participation à la Conférence Mondiale sur la Santé 2025 de Leerink Partners. L'équipe de direction de l'entreprise participera à une discussion informelle prévue pour mardi 11 mars à 15h40 ET.
Les investisseurs et les parties intéressées peuvent accéder à la fois à la présentation en direct et à sa rediffusion via la section 'Événements et Présentations' sur le site web des relations avec les investisseurs de Regulus. L'enregistrement de la présentation restera accessible pendant 90 jours après l'événement.
Regulus Therapeutics (Nasdaq: RGLS), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von mikroRNA-zielgerichteten Arzneimitteln spezialisiert hat, hat seine bevorstehende Teilnahme an der Leerink Partners 2025 Global Healthcare Conference angekündigt. Das Management-Team des Unternehmens wird an einem informellen Gespräch teilnehmen, das für Dienstag, den 11. März um 15:40 Uhr ET angesetzt ist.
Investoren und Interessierte können sowohl auf die Live-Präsentation als auch auf deren Wiederholung über den Bereich 'Veranstaltungen und Präsentationen' auf der Investor-Relations-Website von Regulus zugreifen. Die Aufzeichnung der Präsentation bleibt 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
The live event and replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in
View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-leerink-partners-2025-global-healthcare-conference-302390551.html
SOURCE Regulus Therapeutics Inc.
FAQ
When is Regulus Therapeutics (RGLS) presenting at the Leerink Partners 2025 Conference?
How long will the RGLS Leerink Conference presentation replay be available?
Where can investors access Regulus Therapeutics' (RGLS) Leerink Conference presentation?
What type of presentation will RGLS deliver at the Leerink Partners Conference?
